1. [Cysteine proteinases and their inhibitors in the development of mouse HA-1 hepatoma and antineoplastic therapy].
- Author
-
Poteriaeva ON, Korolenko TA, Svechnikova IG, Zhanaeva SIa, Falameeva OV, Kaledin VI, and Nowicky JW
- Subjects
- Animals, Ascites enzymology, Ascites metabolism, Ascites pathology, Berberine Alkaloids, Cathepsin B metabolism, Cathepsin D metabolism, Cathepsin L, Cathepsins metabolism, Cystatin A, Cystatin C, Cystatins metabolism, Liver Neoplasms, Experimental enzymology, Liver Neoplasms, Experimental metabolism, Male, Mice, Neoplasm Transplantation, Phenanthridines, Alkaloids therapeutic use, Antineoplastic Agents therapeutic use, Cysteine Endopeptidases metabolism, Cysteine Proteinase Inhibitors metabolism, Liver Neoplasms, Experimental drug therapy
- Abstract
Development of murine HA-1 hepatoma was accompanied by increased activity of cathepsin B (in ascitic cells), cathepsin D (in ascitic fluid) and increased activity of procathepsin B. There were some changes of cysteine proteinases in liver and spleen, not involved directly into tumor growth. The most prominent changes included the decreased level of cysteine proteinase inhibitors cystatin C and stefin A in ascitic cells (and to a lesser degree in liver tissue). During tumor development serum cystatin C concentration decreased by 3-times compared to intact mice. Treatment by antitumor drug Ukraine increased life span of mice with HA-1 hepatoma (transplanted intravenously), decreased the increment of tumor weight. In ascite such treatment caused a decrease of number of tumor cells and an increase of number of macrophages. Ukraie (administered once or 5-times in a dose of 0.5 mg per mice) increased cystatin C level, revealing protective mechanism of action.
- Published
- 2004